IQVIA Holdings Inc

IQVNYSE · USD
268.82USD0.00 (-0.32%)
6810

IQVIA Holdings Inc (IQV) Covered Calls

As of September 16, 2026, IQV has 97 covered call opportunities in the coming three months. Return ranges from 1.3 to 51.3% until expiration. Annualized return ranges from 15.2 to 1,372.9%. The nearest expiration is September 18, 2026. Maximum potential profit is $13,833.

Read more

Running IQV covered calls helps you generate consistent income from IQVIA Holdings Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on IQVIA Holdings Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best IQV covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if IQV stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling IQV covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given IQVIA Holdings Inc covered call is worth writing.

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Income-focused investors, long-term IQV holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling IQV covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best IQVIA Holdings Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV percentile72.22% Elevated
  • Market cap (M$)44,248
  • 52 weeks high-1.30%
  • 52 weeks low73.99%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$278.53
    3.61% above the current stock price
  • Dividend
  • Payout ratio0.00%
  • Earnings date2026-11-03
  • P/E33.35
  • Future P/E18.64
  • EPS (ttm)8.06
  • EPS growth next 5 years10.65%

As of September 16, 2026

2026-09-183300.0011.250.100.303043.0011.281372.91-0.04+0.034350.20
2026-09-183290.007.540.102.202043.007.58921.74-0.04+0.14162.10
2026-09-183280.003.830.102.351043.003.87470.57-0.04+0.209352.25
2026-11-2066360.0033.500.053.109038.0033.52185.35-0.02+0.0823.05
2026-10-1631310.0014.960.101.804043.0014.99176.52-0.04+0.0861.70
2026-11-2066350.0029.790.602.958093.0030.01165.97-0.22+0.0912.35
2026-09-183270.000.123.205.10353.001.31159.26-1.19+0.501781.90
2026-11-2066340.0026.080.953.207128.0026.43146.18-0.35+0.10182.25
2026-10-1631300.0011.250.702.753103.0011.51135.48-0.26+0.14142.05
2027-01-15122390.0044.620.152.3012048.0044.68133.66-0.06+0.0642.15

As of September 16, 2026

Sell covered calls with the data behind you

Find the best IQV covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial